RU2015102810A - Функционализированные липосомы, пригодные для доставки биоактивных соединений - Google Patents
Функционализированные липосомы, пригодные для доставки биоактивных соединений Download PDFInfo
- Publication number
- RU2015102810A RU2015102810A RU2015102810A RU2015102810A RU2015102810A RU 2015102810 A RU2015102810 A RU 2015102810A RU 2015102810 A RU2015102810 A RU 2015102810A RU 2015102810 A RU2015102810 A RU 2015102810A RU 2015102810 A RU2015102810 A RU 2015102810A
- Authority
- RU
- Russia
- Prior art keywords
- conjugate
- liposome
- therapeutic agent
- administering
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6915—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1. Конъюгат, содержащий:i) стерол;ii) цепь полиэтиленгликоля, имеющую проксимальный конец и дистальный конец, в котором указанная цепь полиэтиленгликоля ковалентно связана с ее проксимальным концом с i) посредством связи типа алкиловый эфир;iii) направляющий лиганд, способный к селективному связыванию с одним или несколькими рецепторами, представленными на клетке-мишени, при этом указанный направляющий лиганд ковалентно связан с дистальным концом ii).2. Конъюгат по п. 1, в котором стерол является холестерином.3. Конъюгат по п. 1, в котором цепь полиэтиленгликоля имеет количество повторов от 2 до 10.4. Конъюгат по п. 1, в котором направляющий лиганд является пептидом.5. Конъюгат по п. 4, в котором направляющий лиганд содержит последовательность RGD.6. Конъюгат по п. 5, в котором направляющий лиганд является пептидом последовательности SEQ ID NO: 1.7. Липосома, содержащая конъюгат, как определено в п. 1.8. Липосома по п. 7, имеющая мономодальное распределение размера частиц.9. Липосома по п. 8, в котором средний размер частиц составляет от 25 вплоть до 500 нанометров, и средний Ζ потенциал по абсолютной величине составляет от 20 вплоть до 90 мВ.10. Липосома по п. 7, дополнительно содержащая терапевтический агент.11. Липосома по п. 10, в котором терапевтический агент является α-галактозидазой.12. Способ доставки терапевтического агента, включающий введение липосомы по п. 10.13. Способ лечения, включающий введение терапевтически эффективного количества липосомы по п. 10, вместе с фармацевтически приемлемыми вспомогательными веществами или носителями, субъекту, нуждающемуся в таком лечении, включая человека.14. Способ лечения, включающий введение терапевтически эффективного количества липосомы по п. 11, вместе с
Claims (22)
1. Конъюгат, содержащий:
i) стерол;
ii) цепь полиэтиленгликоля, имеющую проксимальный конец и дистальный конец, в котором указанная цепь полиэтиленгликоля ковалентно связана с ее проксимальным концом с i) посредством связи типа алкиловый эфир;
iii) направляющий лиганд, способный к селективному связыванию с одним или несколькими рецепторами, представленными на клетке-мишени, при этом указанный направляющий лиганд ковалентно связан с дистальным концом ii).
2. Конъюгат по п. 1, в котором стерол является холестерином.
3. Конъюгат по п. 1, в котором цепь полиэтиленгликоля имеет количество повторов от 2 до 10.
4. Конъюгат по п. 1, в котором направляющий лиганд является пептидом.
5. Конъюгат по п. 4, в котором направляющий лиганд содержит последовательность RGD.
6. Конъюгат по п. 5, в котором направляющий лиганд является пептидом последовательности SEQ ID NO: 1.
7. Липосома, содержащая конъюгат, как определено в п. 1.
8. Липосома по п. 7, имеющая мономодальное распределение размера частиц.
9. Липосома по п. 8, в котором средний размер частиц составляет от 25 вплоть до 500 нанометров, и средний Ζ потенциал по абсолютной величине составляет от 20 вплоть до 90 мВ.
10. Липосома по п. 7, дополнительно содержащая терапевтический агент.
11. Липосома по п. 10, в котором терапевтический агент является α-галактозидазой.
12. Способ доставки терапевтического агента, включающий введение липосомы по п. 10.
13. Способ лечения, включающий введение терапевтически эффективного количества липосомы по п. 10, вместе с фармацевтически приемлемыми вспомогательными веществами или носителями, субъекту, нуждающемуся в таком лечении, включая человека.
14. Способ лечения, включающий введение терапевтически эффективного количества липосомы по п. 11, вместе с фармацевтически приемлемыми вспомогательными веществами или носителями пациенту с болезнью Фабри.
15. Фармацевтическая композиция, содержащая терапевтически эффективное количество липосом, как определено в п. 10, вместе с фармацевтически приемлемыми вспомогательными веществами и/или носителями.
16. Способ получения конъюгата, как определено в п. 1, включающий следующие этапы:
a) реакция стерола с сульфонилгалогенидом в присутствии основания и растворителя для получения соответствующего сульфонильного сложного эфира;
b) реакция соединения, полученного на этапе a), с полиэтиленгликолем с количеством повторов от 2 до 10 в присутствии растворителя;
c) активация соединения, полученного на этапе b), с дисукцинимидилкарбонатом;
d) реакция соединения, полученного в результате этапа c), с пептидом, содержащим последовательность RGD в присутствии основания и растворителя.
17. Способ получения липосомы, как определено в п. 7, включающий следующие этапы:
a) получение водного раствора, который может необязательно содержать поверхностно-активное вещество;
b) получение раствора, содержащего конъюгат, как определено в любом из пп. 1-6, холестерин и, необязательно, фосфолипид, растворенный в органическом растворителе, где органический раствор увеличен в объеме сжатой текучей средой;
c) необязательно добавление терапевтического агента или к раствору этапа a), или к раствору этапа b) перед увеличением объема этого раствора; и
d) декомпрессия раствора, полученного в результате этапа b), над полученным в результате этапа a) раствором.
18. Липосома, содержащая конъюгат, как определено в п. 5.
19. Липосома по п. 18, дополнительно содержащая терапевтический агент.
20. Липосома по п. 18, дополнительно содержащая терапевтический агент, в котором терапевтический агент является α-галактозидазой.
21. Способ лечения, включающий введение терапевтически эффективного количества липосомы по п. 19, вместе с фармацевтически приемлемыми вспомогательными веществами или носителями субъекту, нуждающемуся в таком лечении, включая человека.
22. Способ лечения, включающий введение терапевтически эффективного количества липосомы по п. 20, вместе с фармацевтически приемлемыми вспомогательными веществами или носителями пациенту с болезнью Фабри.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201231020 | 2012-06-29 | ||
ES201231020 | 2012-06-29 | ||
PCT/EP2013/063646 WO2014001509A1 (en) | 2012-06-29 | 2013-06-28 | Functionalized liposomes useful for the delivery of bioactive compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015102810A true RU2015102810A (ru) | 2016-08-20 |
Family
ID=48700599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015102810A RU2015102810A (ru) | 2012-06-29 | 2013-06-28 | Функционализированные липосомы, пригодные для доставки биоактивных соединений |
Country Status (8)
Country | Link |
---|---|
US (1) | US9744247B2 (ru) |
EP (1) | EP2866839B1 (ru) |
JP (1) | JP6368304B2 (ru) |
CN (1) | CN104507503A (ru) |
BR (1) | BR112014032919B1 (ru) |
ES (1) | ES2696623T3 (ru) |
RU (1) | RU2015102810A (ru) |
WO (1) | WO2014001509A1 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2706298C1 (ru) * | 2018-09-14 | 2019-11-15 | Закрытое Акционерное Общество "Биокад" | НУКЛЕАЗА PaCas9 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160298187A1 (en) * | 2015-04-08 | 2016-10-13 | Verily Life Sciences Llc | Methods of tagging particles for multiplexed functional screening |
WO2016178431A1 (ja) * | 2015-05-07 | 2016-11-10 | 国立大学法人 東京大学 | ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法 |
WO2017189826A1 (en) * | 2016-04-29 | 2017-11-02 | Portage Pharmaceuticals Ltd. | Use of cell-permeable peptides and non-peptide carriers conjugated with nemo binding domain cargo sequence for the treatment of dry eye disease and uveitis |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
WO2022101193A1 (en) | 2020-11-10 | 2022-05-19 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Cell-penetrating peptides |
EP4035658A1 (en) | 2021-01-27 | 2022-08-03 | Consejo Superior de Investigaciones Científicas (CSIC) | Liposomes and its use for enzyme delivery |
CN114469862A (zh) * | 2021-10-20 | 2022-05-13 | 成都科建生物医药有限公司 | 胆固醇调控包封聚多巴胺的方法 |
CN114249791A (zh) * | 2021-12-27 | 2022-03-29 | 北京工商大学 | 一种甾醇衍生的酰胺基寡肽型表面活性剂及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2581828T3 (es) * | 1996-09-13 | 2016-09-07 | Shire Human Genetic Therapies, Inc. | Proceso de purificación de alfa-galactosidasa A |
FR2854896B1 (fr) | 2003-05-16 | 2007-08-17 | Mayoly Spindler Lab | Nouveaux tensioactifs, compositions les comprenant |
JP2009046441A (ja) * | 2007-08-22 | 2009-03-05 | Konica Minolta Holdings Inc | コレステロール誘導体、リポソーム、リポソームの形成方法及びx線用造影剤 |
CN102475682B (zh) * | 2010-11-30 | 2013-03-13 | 沈阳药科大学 | 小檗碱脂质体及其制备方法 |
-
2013
- 2013-06-28 EP EP13732179.0A patent/EP2866839B1/en active Active
- 2013-06-28 RU RU2015102810A patent/RU2015102810A/ru not_active Application Discontinuation
- 2013-06-28 WO PCT/EP2013/063646 patent/WO2014001509A1/en active Application Filing
- 2013-06-28 US US14/411,097 patent/US9744247B2/en active Active
- 2013-06-28 BR BR112014032919-2A patent/BR112014032919B1/pt active IP Right Grant
- 2013-06-28 CN CN201380034806.6A patent/CN104507503A/zh active Pending
- 2013-06-28 ES ES13732179T patent/ES2696623T3/es active Active
- 2013-06-28 JP JP2015519132A patent/JP6368304B2/ja active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2706298C1 (ru) * | 2018-09-14 | 2019-11-15 | Закрытое Акционерное Общество "Биокад" | НУКЛЕАЗА PaCas9 |
Also Published As
Publication number | Publication date |
---|---|
JP6368304B2 (ja) | 2018-08-01 |
JP2015522578A (ja) | 2015-08-06 |
EP2866839B1 (en) | 2018-08-15 |
CN104507503A (zh) | 2015-04-08 |
ES2696623T3 (es) | 2019-01-17 |
BR112014032919A2 (pt) | 2017-08-22 |
BR112014032919A8 (pt) | 2021-07-13 |
EP2866839A1 (en) | 2015-05-06 |
WO2014001509A1 (en) | 2014-01-03 |
US9744247B2 (en) | 2017-08-29 |
US20150190530A1 (en) | 2015-07-09 |
BR112014032919B1 (pt) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015102810A (ru) | Функционализированные липосомы, пригодные для доставки биоактивных соединений | |
TWI653051B (zh) | 腎上腺髓素之聚乙二醇基底前藥及其用途 | |
JP2020063241A5 (ru) | ||
KR102492135B1 (ko) | 페길화된 카르필조밉 화합물 | |
Mansukhani et al. | Peptide amphiphile supramolecular nanostructures as a targeted therapy for atherosclerosis | |
AU2020289730B2 (en) | Pentaaza macrocyclic ring complexes possessing oral bioavailability | |
RU2013121788A (ru) | Ингибиторы репликации вич | |
JP2014527050A (ja) | 担体連結しているトレプロスチニルプロドラッグ | |
ES2859923T3 (es) | Compuestos de disulfuro para el suministro de agentes farmacéuticos | |
WO2012054500A3 (en) | Compositions for drug administration | |
CN1390143A (zh) | 两亲型前药 | |
PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
CN103200950A (zh) | 新颖的耳他汀衍生物及其用途 | |
JP2019524759A (ja) | 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート | |
EP3033056B1 (en) | Peptides for enhancing transdermal delivery | |
CN107708686B (zh) | 氧杂二环庚烷前药 | |
WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
US10376591B2 (en) | Formulations and carrier systems including farnesylthiosalicylic moieties | |
JP2013535494A5 (ru) | ||
IN2014DN00277A (ru) | ||
BRPI1011439B1 (pt) | composlção de alta penetração, composição farmacêutica, sistemas de aplicação terapêutico transdérmico e uso de referida composição | |
NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
WO2009151714A3 (en) | Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions | |
RU2010140888A (ru) | Улучшенные противораковые терапии | |
EP3791897A1 (en) | Hsp90 inhibitor drug conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171117 |